Status:
COMPLETED
Randomized Double-Blind Controlled Clinical Trial
Lead Sponsor:
SerenaGroup, Inc.
Collaborating Sponsors:
Anacapa Technologies Inc
Conditions:
Chronic Wounds
Acute Wounds
Eligibility:
All Genders
18-100 years
Phase:
NA
Brief Summary
The study is a randomized double-blind controlled clinical trial designed to compare the ability of NaOCl to NSS in the reduction of bacterial burden in nonhealing acute and chronic wounds.
Detailed Description
The study is a randomized double-blind controlled clinical trial designed to compare the ability of NaOCl to NSS in the reduction of bacterial burden in nonhealing acute and chronic wounds. Using the ...
Eligibility Criteria
Inclusion
- Adult patients with acute or chronic wounds that have been present for a minimum of 4 weeks.
- A signed and dated informed consent form.
- Subject is willing and able to comply with instructions and scheduled visits.
Exclusion
- The Subject has other concurrent conditions that in the opinion of the Investigator may compromise subject safety.
- The subject's wound has not been present for at least 4 weeks.
Key Trial Info
Start Date :
May 20 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2022
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT04320628
Start Date
May 20 2020
End Date
March 1 2022
Last Update
March 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Serena Group Research Institute
Pittsburgh, Pennsylvania, United States, 15222